Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;6(5):e1629.
doi: 10.1371/journal.pntd.0001629. Epub 2012 May 1.

Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis

Meenakshi Sharma  1 , Rakesh Sehgal, Sukhbir Kaur
Affiliations

Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis

Meenakshi Sharma et al. PLoS Negl Trop Dis. 2012.

Abstract

Background: Most available drugs against visceral leishmaniasis are toxic, and growing limitations in available chemotherapeutic strategies due to emerging resistant strains and lack of an effective vaccine against visceral leishmaniasis deepens the crisis. Antineoplastic drugs like miltefosine have in the past been effective against the parasitic infections. An antineoplastic drug, cisplatin (cis-diamminedichloroplatinum II; CDDP), is recognized as a DNA-damaging drug which also induces alteration of cell-cycle in both promastigotes and amastigotes leading to cell death. First in vivo reports from our laboratory revealed the leishmanicidal potential of cisplatin. However, high doses of cisplatin produce impairment of kidney, which can be reduced by the administration of antioxidants.

Methodology/principal findings: The present study was designed to evaluate the antileishmanial effect of cisplatin at higher doses (5 mg and 2.5 mg/kg body weight) and its combination with different antioxidants (vitamin C, vitamin E and silibinin) so as to eliminate the parasite completely and reduce the toxicity. In addition, various immunological, hematological and biochemical changes induced by it in uninfected and Leishmania donovani infected BALB/c mice were investigated.

Conclusion/significance: A significant reduction in parasite load, higher IgG2a and lower IgG1 levels, enhanced DTH responses, and greater concentration of Th1 cytokines (IFN-γ, IL-2) with a concomitant down regulation of IL-10 and IL-4 pointed towards the generation of the protective Th1 type of immune response. A combination of cisplatin with antioxidants resulted in successful reduction of nephrotoxicity by normalizing the enzymatic levels of various liver and kidney function tests. Reduction in parasite load, increase in Th1 type of immune responses, and normalization of various biochemical parameters occurred in animals treated with cisplatin in combination with various antioxidants as compared to those treated with the drug only. The above results are promising as antioxidants reduced the potential toxicity of high doses of cisplatin, making the combination a potential anti-leishmanial therapy, especially in resistant cases.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Parasite load in terms of LDU in different groups of animals.
The data are presented as mean±S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin.* - p<0.001. No significant difference was found in groups: Infected+5 mg CP vs Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin and Infected only vs Infected+Silibinin/Infected+VitE+VitC/Infected+VitE+VitC+Silibinin. LDU- Leishman Donovan Units.
Figure 2
Figure 2. Percentage increase in footpad thickness (DTH response) in different groups of animals.
The data are presented as mean±S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. † -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001.
Figure 3
Figure 3. Levels of Leishmania-specific IgG antibodies in serum samples of different groups of animals.
A -IgG, B -IgG1 and C -IgG2a. The data are presented as mean±S.D. of six mice per group. *,# -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. †,§ -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001; #,§-p<0.05.
Figure 4
Figure 4. Cytokine levels in culture supernatants of spleen cells of different groups of animals.
A- IFN-γ, B-IL-2. The data are presented as mean±S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. † -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001.
Figure 5
Figure 5. Cytokine levels in culture supernatants of spleen cells of different groups of animals.
A- IL-10, B- IL-4. The data are presented as mean±S.D. of six mice per group. *,# -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. † -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001; #-p<0.05.
Figure 6
Figure 6. Total leucocyte count and hemoglobin levels in different groups of animals.
A- Total Leukocyte Count, B- Hemoglobin levels. The data are presented as mean±S.D. of six mice per group. *,# -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. †,§ -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001; #,§-p<0.05.
Figure 7
Figure 7. SGOT, SGPT and LDH activity in serum samples of different groups of animals.
A- SGOT, B-SGPT, C-LDH. The data are presented as mean±S.D. of six mice per group.* -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. † -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001.
Figure 8
Figure 8. Blood urea and creatinine levels in serum samples of different groups of animals.
A- Blood Urea, B- Creatinine. The data are presented as mean±S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. †,§ -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001; §-p<0.05.
Figure 9
Figure 9. Sodium, phosphate and chloride levels in serum samples of different groups of animals.
A- Sodium, B- Phosphate, C- Chloride. The data are presented as mean±S.D. of six mice per group.* -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. †,§ -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001; §-p<0.05.
Figure 10
Figure 10. Calcium and magnesium levels in serum samples of different groups of animals.
A- Calcium, B- Magnesium. The data are presented as mean±S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. †,§ -p value: Infected+5 mg CP vs. Infected+5 mg CP+Silibinin/Infected+5 mg CP+VitE+VitC/Infected+5 mg CP+VitE+VitC+Silibinin. *,†-p<0.001; §-p<0.05.
See this image and copyright information in PMC

References

    1. Herwaldt BL. Leishmaniasis. Lancet. 1999;354(9185):1191–1199. - PubMed
    1. Sundar S, Chatterjee M. Visceral leishmaniasis – current therapeutic modalities. Indian J Med Res. 2006;123(3):345–352. - PubMed
    1. Murray HW. Clinical and experimental advances in the treatment of visceral leishmaniasis. Antimicrob Agents Chemother. 2001;45(8):2185–2197. - PMC - PubMed
    1. Kshirsagar NA, Bodhe P, Kotwani RN. Targeted drug delivery in visceral leishmaniasis. J Parasit Dis. 1997;21:21–24.
    1. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg. 1995;89(2):219–223. - PubMed

Publication types

MeSH terms